

LIST OF TABLES

Table No.	Table Captions	Page No.
CHAPTER-IV		
4.1	Densitometry analysis of SDS-PAGs (reduced) of crude WI RVV, EI RVV (RVV B and RVV N), and SI RVV	70
4.2a	List of ions detected in WI RVV by MALDI-TOF-MS analysis	70
4.2b	List of ions detected in EI RVV (B) by MALDI-TOF-MS analysis	71
4.2c	List of ions detected in EI RVV (N) by MALDI-TOF-MS analysis	71
4.2d	List of ions detected in SI RVV by MALDI-TOF-MS analysis	72
4.3a	Summary of the identified proteins in WI RVV by LC-MS/MS analysis followed by database search against the Viperidae family of proteins of the NCBI database	80
4.3b	List of all the proteins identified by LC-MS/MS analysis of anion-exchange fractions of WI RVV. The table shows the identified peptide ions, their mass, charge (z), score for the ID, ΔM (ppm), and modified residues	93
4.4a	Summary of the identified proteins in EI RVV (B) and EI RVV (N) by LC-MS/MS analysis and database search against Viperidae family of proteins of the NCBI database	106
4.4b	List of all the proteins identified by LC-MS/MS analysis of GF fractions of EI RVV (B). The table shows the identified peptide ions, their m/z, charge (z), score for the ID, ΔM (ppm), and modified residues	133
4.4c	List of all the proteins identified by LC-MS/MS analysis of GF fractions of EI RVV (N). The table shows the identified peptide ions, their m/z, charge (z), score for the ID, ΔM (ppm), and modified residues	146
4.5a	Summary of the identified proteins in SI RVV by LC-MS/MS analysis and database search against the Viperidae family of proteins of the NCBI database	162
4.5b	List of all the proteins identified by LC-MS/MS analysis of SDS-PAGE bands of SI RVV. The table shows the identified peptide ions, their m/z, charge (z), score for the ID, ΔM (Da), and modified residues	178
4.6	Distribution of toxin isoforms identified in RVV samples from different geographical locations of India by proteomic analysis	191
4.7	A comparison of enzymatic and esterolytic activities exhibited by RVV from different regions of the India	193
4.8a	Assay of enzymatic and esterolytic activities of WI RVV and its GF fractions	195
4.8b	Assay of enzymatic and esterolytic activities of EI RVV (B) and its GF fractions	196

Table No.	Table Captions	Page No.
4.8c	Assay of enzymatic and esterolytic activities of EI RVV (N) and its GF fractions	197
4.9	A comparison of pharmacological properties exhibited by RVV from different regions of India	199
4.10a	Some pharmacological properties of WI RVV (40 µg/ml) and its GF fractions (10 µg)	200
4.10b	Some pharmacological properties of EI RVV (B) (40 µg/ml) and its GF fractions (10 µg)	201
4.10c	Some pharmacological properties of EI RVV (N) (40 µg/ml) and its GF fractions (10 µg)	202
CHAPTER-V		
5.1	A summary of purification of Ruviapyrase from WI RVV	245
5.2	Results of <i>de novo</i> sequencing and subsequent BLASTp search of the <i>de novo</i> peptides generated from Ruviapyrase by PEAKS 7.0 software.	248
5.3	Substrate specificity of Ruviapyrase against ATP, ADP, AMP, and BNPP substrates	251
5.4	Effect of Mg ²⁺ , Ca ²⁺ , and Zn ²⁺ ions on ATPase and ADPase activities of Ruviapyrase (25 nM)	251
5.5	Kinetic parameters of Ruviapyrase (25 nM) against ATP or ADP substrate	253
5.6	Cytotoxicity and haemolytic activities of Ruviapyrase	256

LIST OF FIGURES

Figure No.	Figure Captions	Page No.
CHAPTER-I		
1.1	Regional estimates of envenomings due to snakebite (low estimate)	4
1.2	Estimated deaths and standardized death rates in Indian states with high prevalence of snakebite mortality	6
1.3	Photographs of adult Russell's Viper	8
1.4	General distribution of the RV (<i>Daboia russelii</i>) on the Indian sub-continent	9
1.5a	A live specimen of Russell's Viper with venom oozing out of its fangs	10
1.5b	Position of the venom gland with the accessory gland and their primary and secondary ducts, and fang in a Viperid snake	10
1.6	A schematic diagram of a typical mass spectrometer	12
1.7	Schematic diagram of an LTQ hybrid mass spectrometer containing linear ion trap and orbitrap mass analyzers	13
CHAPTER-II		
2.1	A schematic representation of the proteomic workflow to analyze RVV samples from different regions of the Indian sub-continent	34
2.2	The venom proteome of Sri Lankan <i>Daboia russelii</i>	36
2.3	The venom proteome of captive specimens of Pakistani <i>Daboia russelii</i>	37
2.4	The venom proteome of wild specimens of Pakistani <i>Daboia russelii</i>	38
CHAPTER-IV		
4.1a	12.5% SDS-PAGE analysis of crude WI RVV (50 µg) under non-reduced (lane 1) and reduced (lane 2) conditions	69
4.1b	12.5% SDS-PAGE analysis of crude EI RVV (B) and EI RVV (N) (80 µg) under non-reduced (lanes 1 and 2, respectively) and reduced (lane 4 and 5, respectively) conditions	69
4.1c	12.5% SDS-PAGE analysis of crude SI RVV (500 µg) under non-reduced (lane 1) and reduced (lane 2) conditions	69
4.2	Fractionation of WI RVV (200 mg dry weight) on a HiLoad 16/600 Superdex 75 pg GF column	73
4.3a-b	Fractionation of WI RVV GF1 and GF2 on a FPLC HiTrap Q FF anion-exchange column	73
4.3c-j	Fractionation of WI RVV GF3 to GF10 on a FPLC HiTrap Q FF anion-exchange column	74
4.4	Distribution of anionic, cationic and/or neutral proteins of WI RVV in its GF fractions	75
4.5	12.5% SDS-PAGE analysis of WI RVV GF fractions under non reduced and reduced conditions	75

Figure No.	Figure Captions	Page No.
4.6	Fractionation of EI RVV (B) and EI RVV (N) (35 mg protein) on a HiLoad 16/600 Superdex 75 pg GF column	76
4.7	12.5% SDS-PAGE analysis of GF fractions of EI RVV (B) and EI RVV (N) under non reduced and reduced conditions	77
4.8	12.5% SDS-PAGE analysis of SI RVV (500 µg protein) under reduced condition (lane 1)	78
4.9a	Protein family composition of WI RVV proteome	79
4.9b	Alignment of tryptic and semi-tryptic peptide sequences identified in WI RVV with Viperidae proteins from NCBI database	85
4.10a, b	Protein family composition of EI RVV (B) and EI RVV (N)	105
4.10c	Alignment of tryptic and semi-tryptic peptide sequences identified in EI RVV (B) with Viperidae proteins from NCBI database	115
4.10d	Alignment of tryptic and semi-tryptic peptide sequences identified in EI RVV (N) with Viperidae proteins from NCBI database	124
4.11a	Protein family composition of SI RVV	161
4.11b	Alignment of tryptic and semi-tryptic peptide sequences identified in SI RVV with Viperidae proteins from NCBI database	168
4.12a	A Venn diagram representing the distribution of shared and unique proteins/toxins among RVV samples from different parts of India	192
4.12b, c	Variation in relative abundance of enzymatic proteins and non-enzymatic proteins in RVV samples from WI, SI, and Burdwan and Nadia districts representing EI RVV samples	192
4.13	Prothrombin (PTH) activation by crude RVVs (40 µg/ml) from different regions of India	198
4.14a	Neutralization of enzyme activities of WI RVV, EI RVV (B), EI RVV (N), and SI RVV by BSVL, PSVPL, VBPL, and Bio-E PAVs	203
4.14b,c	Neutralization of enzyme activities of WI RVV, EI RVV (B), EI RVV (N), and SI RVV by PSVPL and VBPL PAVs	204
4.14d	Neutralization of enzyme activities of WI RVV, EI RVV (B), EI RVV (N), and SI RVV by Bio-E PAV	205
4.15	Neutralization of enzyme activities of WI RVV by BSVL PAV and VINS MAV at 1:10 (venom: antivenom; protein: protein) ratio	205
4.16a,b	Neutralization of pharmacological properties of WI RVV, EI RVV (B), EI RVV (N), and SI RVV by BSVL, and PSVPL PAVs	206
4.16c,d	Neutralization of pharmacological properties of WI RVV, EI RVV (B), EI RVV (N), and SI RVV by VBPL and Bio-E PAVs	207
4.17	Neutralization of pharmacological properties of WI RVV by BSVL PAV and VINS MAV at 1:10 (venom: antivenom; protein: protein) ratio	208
4.18a,b	Immunological cross-reactivity of WI and EI RVV (B) and their GF fractions with commercial PAV and/or MAV by ELISA	209

Figure No.	Figure Captions	Page No.
4.18c,d	Immunological cross-reactivity of EI RVV (N) and its GF fractions, and SI RVV with commercial PAV by ELISA	210
4.19a-d	Immunological cross-reactivity of WI RVV, EI RVV, and SI RVV with commercial PAV and/or MAV by Western blot analysis	211
4.20	Densitometry analysis of the immuno blots of RVV samples detected by commercial PAVs	212
4.21a-c	Immunological cross-reactivity of GF fractions of WI RVV, EI RVV (B), and EI RVV (N) with commercial PAV (BSVL) by Western blot analysis	212
4.22a	12.5% SDS-PAGE analysis of WI RVV, PAV-immuno-affinity column unbound and bound fractions of WI RVV	213
4.22b	Percentage of unbound proteins of WI RVV eluted from immuno-affinity columns coupled with PAV (BSVL and PSVPL) as calculated from MS2 based label-free quantification method	213
4.23	12.5% SDS-PAGE analysis of EI RVV samples and their PAV-immuno-affinity column unbound and bound fractions	214
4.24a, b	Percentage of unbound proteins of EI RVV (B), and EI RVV (N) eluted from immuno-affinity columns coupled with PAV (BSVL and PSVPL) as calculated from MS2 based label-free quantification method	215
4.25a	12.5% SDS-PAGE analysis of SI RVV, PAV-immuno-affinity column unbound and bound fractions of SI RVV	215
4.25b	Percentage of unbound proteins of SI RVV eluted from immuno-affinity columns coupled with PAV (BSVL and PSVPL) as calculated from an average of MS1 (Summed Peptide-Spectrum Match Precursor Intensity) and MS2 (NSAF) based label-free quantification methods	215

CHAPTER-V

5.1	Fractionation of WI RVV GF1 on an FPLC HiTrap Q FF anion exchange column	243
5.2	RP-HPLC analysis of WI RVV GF1 HiQ-8 on a C ₁₈ -RPHPLC column (2.1 × 150 mm, 3 μm)	244
5.3	Determination of purity and molecular mass of Ruviapyrase by SDS-PAGE analysis under reduced and non-reduced conditions	246
5.4	MALDI-TOF-MS spectrum of Ruviapyrase showing signal at m/z 83041.02 corresponding to a single species with a molecular mass of 83.0 kDa	246
5.5a	Dose-dependent ATPase and ADPase activities of Ruviapyrase determined by biochemical analysis	247
5.5b	RP-HPLC analysis of kinetics of ATP and ADP hydrolysis by Ruviapyrase on an Acclaim 300 C ₁₈ column (4.6 × 150 mm, 3 μm) pre-equilibrated with 50 mM sodium phosphate buffer, pH 6.0 (solvent A)	249

Figure No.	Figure Captions	Page No.
5.6	A comparison of ATPase and ADPase activities of Ruviapyrase and WI RVV determined by biochemical analysis	250
5.7	Effect of chemical inhibitors on catalytic activities of Ruviapyrase	252
5.8a, b	Determination of <i>Km</i> and <i>Vmax</i> of Ruviapyrase (25 nM) against ATP and ADP (0.1-2.5mM)	253
5.9	Determination of N-linked glycosylation in Ruviapyrase	254
5.10a, b	Spectrofluorometric interaction of ATP and ADP with Ruviapyrase	255
5.11a, b	One site-specific binding curve showing the change in the maximum fluorescence intensity (λ_{max}) of ATP (50 μ M) and ADP (50 μ M) by different concentrations (0.25-2.5 nM) of Ruviapyrase	256
5.12	Effect of Ruviapyrase on platelet-rich plasma (PRP) and ADP-induced platelet aggregation	257
5.13	Neutralization of ATPase, ADPase and platelet deaggregation activities of Ruviapyrase by commercial PAV and MAV	258
5.14	Immuno cross-reactivity of venom components with commercial MAV and PAV by ELISA	258

ABBREVIATIONS

Abbreviation	Full form
1D SDS-PAGE	One dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis
2D SDS-PAGE	Two dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis
APase	Aminopeptidase
ACN	Acetonitrile
ADP	Adenosine diphosphate
AEX	Anion-exchange
ALC	Average local confidence
AMP	Adenosine monophosphate
AP	Andhra Pradesh
APTT	Activated partial thromboplastin time
ARF	Acute renal failure
ATP	Adenosine triphosphate
BAEE	N α -benzoyl-L-arginine ethyl ester hydrochloride
BCIP/NBT	5-bromo-4-chloro-3'-indolyphosphate/nitro-blue tetrazolium
Bio-E	Biological E Limited
BLAST	Basic local alignment search tool
BNPP	bis- <i>p</i> -nitro-phenyl phosphate
BR	Bihar
BSA	Bovine serum albumin
BSVL	Bharat serum and Vaccines Ltd.
CG	Chhattisgarh
CID	Collision-induced dissociation
CP	Carboxypeptidase
cRAP	Common repository of adventitious proteins
CRISP	Cysteine-rich secretory protein
CTAB	Cetrimonium bromide
CV	Column volumes
DDA	Data-dependent acquisition
DIA	Data-independent acquisition
Dis	Disintegrin
DTT	Dithiothreitol
EDTA	Ethylenediaminetetraacetic acid
EI	Eastern India
EI RVV (B)	Russell's Viper venom from Burdwan
EI RVV (N)	Russell's Viper venom from Nadia
ELISA	Enzyme-linked immunosorbent assay
ESI	Electrospray ionization
FAD	Flavin adenine dinucleotide
FDR	False discovery rate

Abbreviation	Full form
FPLC	Fast Protein Liquid Chromatography
FT	Fourier transform
FXa	Factor Xa
GBD	Global burden of disease
GC	Glutaminy cyclase
GFC	Gel filtration chromatography
GJ	Gujarat
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
Hya	Hyaluronidase
IAA	Iodoacetamide
IgG	Immunoglobulin G
ISCICS	Irula Snake Catcher's Industrial Cooperative Society
JH	Jharkhand
KA	Karnataka
kDa	Kilodalton
KSPI	Kunitz-type serine protease inhibitor
kV	Kilo volt
LAAO	L-amino acid oxidase
LC-MS/MS	Liquid chromatography-tandem mass spectrometry
LD50	Median lethal dose
m/z	Mass to charge
MALDI-TOF-MS	Matrix-assisted laser desorption/ionization -Time of flight - mass spectrometry
MAV	Monovalent antivenom
MH	Maharashtra
MP	Madhya Pradesh
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MW	Molecular weight
NCBI	National Center for Biotechnology Information
NGF	Nerve growth factor
NHS	N-hydroxysuccinimide
NIH	National Institutes of Health
NSAF	Normalized spectral abundance factor
NT	5'-nucleotidase
OR	Orissa
PAV	Polyvalent antivenom
PBS	Phosphate buffered saline
PDE	Phosphodiesterase
Pi	Inorganic phosphate
PLA ₂	Phospholipase A ₂
PLB	Phospholipase B
PMSF	Phenylmethylsulfonyl fluoride
ppm	Parts per million

Abbreviation	Full form
PPP	Platelet poor plasma
PRP	Platelet rich plasma
PSVPL	Premium Serum and Vaccines Pvt. Ltd.
PT	Prothrombin time
PTM	Post translational modification
RJ	Rajasthan
RP-HPLC	Reversed-phase high-performance liquid chromatography
RP-UHPLC	Reversed-phase ultra high-performance liquid chromatography
RV	Russell's Viper
RVV	Russell's Viper venom
SI	Southern India
SVMP	Snake venom metalloprotease
SVSP	Snake venom serine protease
SVTLE	Snake venom thrombin-like enzymes
TAME	N α -p-tosyl-L-arginine methyl ester hydrochloride
TBS	Tris buffered saline
TCA	Trichloroacetic acid
TEMED	Tetramethylethylenediamine
TFA	Trifluoroacetic acid
TMB/H ₂ O ₂	3,3,5,5'-tetramethylbenzidine/hydrogen peroxide
TN	Tamil Nadu
UP	Uttar Pradesh
VBPL	Virchow Biotech Pvt. Ltd.
VEGF	Vascular endothelial growth factor
VINS	Vins Bioproducts Limited
WB	West Bengal
WHO	World Health Organization
WI	Western India